Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

HPV testing and Pap test: role for a combined approach in a non-screened population.

Marchetti I, Zavaglia K, Bertacca G, Aretini P, Matteoli B, Viacava P, Prato B, De Punzio C, Genazzani AR, Bevilacqua G, Di Coscio G.

Int J Biol Markers. 2006 Jul-Sep;21(3):149-56.

PMID:
17013796
2.

Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear.

De Francesco MA, Gargiulo F, Schreiber C, Ciravolo G, Salinaro F, Manca N.

J Virol Methods. 2008 Jan;147(1):10-7. Epub 2007 Sep 12.

PMID:
17854914
4.
5.

Correlation of Pap smear, cervical biopsy, and clinical follow-up with an HPV typing microarray system.

Nuovo GJ, Bartholomew D, Jung WW, Han IK, Um T, Grabarz DF, Lee DJ, McCabe RT.

Diagn Mol Pathol. 2008 Jun;17(2):107-11. doi: 10.1097/PDM.0b013e318161e4dd.

PMID:
18382353
6.

Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications.

Varnai AD, Bollmann M, Bankfalvi A, Speich N, Schmitt C, Griefingholt H, Kovács K, Klozoris C, Bollmann R.

Oncol Rep. 2008 Feb;19(2):457-65.

PMID:
18202795
7.

Comparison of three management strategies for patients with atypical squamous cells of undetermined significance, after six months delay: a three-year experience in an Iranian university hospital.

Yarandi F, Shojaei H, Eftekhar Z, Izadi-Mood N.

Aust N Z J Obstet Gynaecol. 2009 Apr;49(2):207-10. doi: 10.1111/j.1479-828X.2009.00960.x.

PMID:
19432613
8.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13.

PMID:
19141778
9.

Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study.

Derchain SF, Sarian LO, Naud P, Roteli-Martins C, Longatto-Filho A, Tatti S, Branca M, Erzen M, Serpa-Hammes L, Matos J, Gontijo RC, Bragança JF, Lima TP, Maeda MY, Lörincz A, Dores GB, Costa S, Syrjänen S, Syrjänen K.

J Med Screen. 2008;15(2):97-104. doi: 10.1258/jms.2008.007061.

PMID:
18573778
10.

HPV DNA testing as an adjunct in the management of patients with low grade cytological lesions in Finland.

Tarkkanen J, Auvinen E, Nieminen P, Malmi R, Vartiainen J, Timonen T, Laurila P, Räisänen I, Unnerus HA, Sakki A, Mattila P, Van Den Brule AV, Tapper AM.

Acta Obstet Gynecol Scand. 2007;86(3):367-72.

PMID:
17364315
11.

Prognostic markers of high-grade squamous intraepithelial lesions: the role of p16INK4a and high-risk human papillomavirus.

Eleutério J Jr, Giraldo PC, Gonçalves AK, Cavalcante DI, de Almeida Ferreira FV, Mesquita SM, Morais SS.

Acta Obstet Gynecol Scand. 2007;86(1):94-8.

PMID:
17230296
12.
13.

Molecular testing of human papillomavirus in cervical specimens.

Gazzaz FB.

Saudi Med J. 2007 Dec;28(12):1810-8.

PMID:
18060207
14.

Human papillomavirus DNA integration and messenger RNA transcription in cervical low- and high-risk squamous intraepithelial lesions in Austrian women.

Manavi M, Hudelist G, Fink-Retter A, Gschwantler-Kaulich D, Pischinger K, Czerwenka K.

Int J Gynecol Cancer. 2008 Mar-Apr;18(2):285-94. Epub 2007 Jun 22.

PMID:
17587315
15.

[Detection and typing of human papilloma virus by polymerase chain reaction and hybridization assay in cervical samples with cytological abnormalities].

Ergünay K, Misirlioğlu M, Firat P, Tuncer ZS, Tuncer S, Yildiz I, Ustaçelebi S.

Mikrobiyol Bul. 2008 Apr;42(2):273-82. Turkish.

PMID:
18697425
16.

Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005.

Datta SD, Koutsky LA, Ratelle S, Unger ER, Shlay J, McClain T, Weaver B, Kerndt P, Zenilman J, Hagensee M, Suhr CJ, Weinstock H.

Ann Intern Med. 2008 Apr 1;148(7):493-500.

PMID:
18378945
17.

Human papillomavirus genotyping for the eight oncogenic types can improve specificity of HPV testing in women with mildly abnormal Pap results.

Guo M, Lin CY, Gong Y, Cogdell DE, Zhang W, Lin E, Sneige N.

Mod Pathol. 2008 Aug;21(8):1037-43. doi: 10.1038/modpathol.2008.93. Epub 2008 May 23.

18.

Baseline human papillomavirus status of women with abnormal smears in cervical screening: a 5-year follow-up study in The Netherlands.

Prinsen CF, Fles R, Wijnen-Dubbers CW, de Valk HA, Klaassen CH, Mravunac M, Horrevorts AM, Thunnissen FB.

BJOG. 2007 Aug;114(8):951-7. Epub 2007 Jun 18.

19.

Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia.

Hesselink AT, van Ham MA, Heideman DA, Groothuismink ZM, Rozendaal L, Berkhof J, van Kemenade FJ, Massuger LA, Melchers WJ, Meijer CJ, Snijders PJ.

J Clin Microbiol. 2008 Oct;46(10):3215-21. doi: 10.1128/JCM.00476-08. Epub 2008 Aug 6.

20.

HPV detection and genotyping as an earlier approach in cervical cancer screening of the female genital tract.

Krambeck WM, Cadidé RM, Dalmarco EM, de Cordova CM.

Clin Exp Obstet Gynecol. 2008;35(3):175-8.

PMID:
18754286

Supplemental Content

Support Center